Imatinib, dasatinib and nilotinib: A review of adverse cutaneous reactions with emphasis on our clinical experience

V. Brazzelli, V. Grasso, G. Borroni

Research output: Contribution to journalArticle

Abstract

In the last years, several tyrosine kinase inhibitors (TKIs) have been developed and approved for human cancer treatment. Imatinib mesylate was the first of this novel family of drugs that target cancer-specific molecules and signalling pathways. The appearance of imatinib resistances led to the introduction of second-generation TKIs with higher potency and selectivity, such as dasatinib and nilotinib. However, the range of activity of these agents is not simply directed at tumour cells. Patients and their clinicians are indeed frequently confronted with the cutaneous side-effects associated with the employ of these drugs, which represent the most common non-hematological adverse reactions. For this reason, a systematic dermatological survey of patients receiving these therapies is highly important, and an early and appropriate dermatological treatment is required. In this review, we analyse the clinical and pathological characteristics of the most commonly reported adverse skin events associated with first- and second-generation tyrosine kinase inhibitors, with a particular emphasis on our clinical experience.

Original languageEnglish
Pages (from-to)1471-1480
Number of pages10
JournalJournal of the European Academy of Dermatology and Venereology
Volume27
Issue number12
DOIs
Publication statusPublished - Dec 2013

ASJC Scopus subject areas

  • Dermatology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Imatinib, dasatinib and nilotinib: A review of adverse cutaneous reactions with emphasis on our clinical experience'. Together they form a unique fingerprint.

  • Cite this